SavedAdd your journal

Journals / Journal of critical and intensive care (Online) / 2021 / Cilt: 12 - Sayı: 2

Transfusion-Related Acute Lung Injury (TRALI) After Convalescent Plasma Therapy in COVID-19 Patient

Buket MERMİT ÇİLİNGİR
Selvi AŞKAR
Pages
60–63
Publication Date
2022-10-19
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

We aimed to present our case to discuss the difficulty of this situation to differentiate from COVID-19 related ARDS

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The coronavirus disease 2019 (COVID-19) continues to spread all around the world.
📊
Key Findings & Data:Mortality and morbidity rates are increasing-up to now.
💡
Conclusion & Impact:We aimed to present our case to discuss the difficulty of this situation to differentiate from COVID-19 related ARDS
🔬Design:Research Article
📍Scope:2019 Verileri
⚙️Variables:Domain Parameters

Abstract

The coronavirus disease 2019 (COVID-19) continues to spread all around the world. Mortality and morbidity rates are increasing-up to now. Although convalescent plasma therapy can be thought to be useful in the treatment of COVID-19, it carries potential risks, such as transfusion-related acute lung injury (TRALI). In COVID-19 infection, tachypnea, tachycardia, increased need for oxygenation, and the presence of bilateral widespread infiltrates on radiological imagings are evaluated as acute respiratory distress syndrome (ARDS). This clinical situation may develop independently from disease progression in patients receiving convalescent plasma therapy and it is called TRALI. We aimed to present our case to discuss the difficulty of this situation to differentiate from COVID-19 related ARDS

🔖

Cite This Article

ÇİLİNGİR, B. M., AŞKAR, S. (2022). Transfusion-Related Acute Lung Injury (TRALI) After Convalescent Plasma Therapy in COVID-19 Patient. Journal of critical and intensive care (Online), Cilt: 12 - Sayı: 2, 60–63. https://ajindex.com/articles/562271

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. World Health Organization (2021). Novel Coronavirus (2019- nCoV) situation reports. https://www.who.int/emergencies/ diseases/novel-coronavirus-2019/situation-reports 2. Cao Y-C, Deng Q-X, Dai S-X. Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: an evaluation of the evidence. Travel Med Infect Dis 2020
  2. 101647. [CrossRef] 3. Cao B, Wang Y, Wen D, et al. A trial of Lopinavir-Ritonavir in adults hospitalized with severe Covid-19. N Engl J Med 2020
  3. 1787– 99. [CrossRef] 4. Gautret P, Lagier J-C, Parola P, et al. Hydroxychloroquine and nazithromycin as a treatment of COVID-19: results of an open- label non-randomized clinical trial. Int J Antimicrob Agents 2020
  4. 105949. [CrossRef] 5. Michot J-M, Albiges L, Chaput N, et al. Tocilizumab, an anti-IL6 receptor antibody, to treat Covid-19-related respiratory failure: a case report. Ann Oncol 2020
  5. 961–4. [CrossRef] 6. Zhang C, Wu Z, Li J-W, et al. The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality. Int J Antimicrob Agents 2020
  6. 105954. [CrossRef] 7. Cunningham AC, Goh HP, Koh D. Treatment of COVID-19: old tricks for new challenges. Crit Care 2020
  7. [CrossRef] 8. Luke TC, Kilbane EM, Jackson JL, et al. Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? Ann Intern Med 2006
  8. 599–609. [CrossRef] 9. Hung IF, To KK, Lee C-K, et al. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis 2011
  9. 447–56. [CrossRef] 10. Mair-Jenkins J, Saavedra-Campos M, Baillie JK, et al.The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-nalysis. J Infect Dis 2015
  10. 80–90. [CrossRef] 11. Shen C,Wang Z, Zhao F, et al.Treatment of 5 critically Ill patients with COVID-19 with convalescent plasma. JAMA 2020
  11. 1582–9. [CrossRef] 12. Zhang B, Liu S, Tan T, et al. Treatment with convalescent plasma for critically ill patients with SARS-CoV-2 infection. Chest 2020
  12. e9–13. [CrossRef] 13. Vlaar APJ, Juffermans NP. Transfusion-related acute lung injury: a clinical review. Lancet 2013
  13. 984–94. [CrossRef] 14. Arabi Y, Balkhy H, Hajeer AH, et al. Feasibility, safety, clinical, and laboratory effects of convalescent plas